AR038949A1 - Compuestos de quinazolina utiles en terapia, procedimiento de preparacion y compuesto util en su preparacion - Google Patents
Compuestos de quinazolina utiles en terapia, procedimiento de preparacion y compuesto util en su preparacionInfo
- Publication number
- AR038949A1 AR038949A1 ARP030100858A ARP030100858A AR038949A1 AR 038949 A1 AR038949 A1 AR 038949A1 AR P030100858 A ARP030100858 A AR P030100858A AR P030100858 A ARP030100858 A AR P030100858A AR 038949 A1 AR038949 A1 AR 038949A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- preparation
- independently
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000037007 arousal Effects 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los compuestos de fórmula (1): o sales o solvatos farmacéuticamente aceptables de los mismos, en la que R1 representa alquilo C1-4; R2 representa halo, alquilo C1-4, cicloalquilo C3-6, cicloalquiloxi C3-6, -SO2(alquilo C1-4), alquiloxi C1-4 opcionalmente sustituido, Het o -OHet; R3 representa un grupo bicíclico de fórmula (2) en la que X e Y se seleccionan entre C y N, con la condición de que al menos uno sea C; El anillo A junto con X e Y representa un anillo aromático de 5 o 6 miembros que contiene 0, 1, 2 o 3 átomos de nitrógeno en el anillo; n es 0, 1 o 2 L representa independientemente un enlace directo, alquileno C1-4 o alcoxialquileno C1-4; R4 representa independientemente H, -NR5R6, cicloalquilo C3-6, -OR7, Het1 o Het4; R5 y R6 se seleccionan independientemente entre H, cicloalquilo C3-6, cicloalquil C3-6-alquileno C1-4, -SO2(alquilo C1-4) y alquilo C1-4 opcionalmente sustituido; R7 se selecciona entre H, alquilo C1-4, alcoxialquilo C1-4, cicloalquilo C3-6, Het2 y alquil C1-4-Het3; R8 es H o alquilo C1-4; Het, Het1, Het2 y Het3 representan independientemente un grupo heterocíclico saturado de 4 a 7 miembros opcionalmente sustituido que puede ser mono- o bicíclico y que contiene uno o más heteroátomos seleccionados entre N, O o S; Het4 representa un grupo heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido que contiene uno o más heteroátomos seleccionados entre N, O o S; R9 es H o alquilo C1-4; R10 y R11 se seleccionan independientemente entre H y alquilo C1-4; son útiles en el tratamiento de la hipertensión, infarto de miocardio, disfunción eréctil masculina (MED), hiperlipidemia, arritmia cardiaca, glaucoma e hiperplasia prostática benigna (BPH). También encuentran utilidad en el tratamiento de la disfunción de excitación sexual femenina (FSAD). Procedimiento de preparación de los mismos y compuestos útil en la preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0206033.3A GB0206033D0 (en) | 2002-03-14 | 2002-03-14 | Compounds useful in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038949A1 true AR038949A1 (es) | 2005-02-02 |
Family
ID=9932974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100858A AR038949A1 (es) | 2002-03-14 | 2003-03-12 | Compuestos de quinazolina utiles en terapia, procedimiento de preparacion y compuesto util en su preparacion |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6936619B2 (es) |
| EP (1) | EP1483257B1 (es) |
| JP (1) | JP2005532275A (es) |
| AR (1) | AR038949A1 (es) |
| AT (1) | ATE339414T1 (es) |
| AU (1) | AU2003209594A1 (es) |
| BR (1) | BR0308407A (es) |
| CA (1) | CA2479016A1 (es) |
| DE (1) | DE60308332T2 (es) |
| ES (1) | ES2271618T3 (es) |
| GB (1) | GB0206033D0 (es) |
| GT (1) | GT200300059A (es) |
| HN (1) | HN2003000100A (es) |
| MX (1) | MXPA04008939A (es) |
| PA (1) | PA8569501A1 (es) |
| PE (1) | PE20040265A1 (es) |
| TW (1) | TW200305420A (es) |
| UY (1) | UY27711A1 (es) |
| WO (1) | WO2003076427A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900220B2 (en) * | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| ATE335744T1 (de) * | 2002-08-07 | 2006-09-15 | Novartis Pharma Gmbh | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
| US20040132728A1 (en) * | 2002-09-17 | 2004-07-08 | Pfizer Inc | Combinations of atorvastatin and alpha1adrenergic receptor antagonists |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| DE602004007387T2 (de) * | 2003-07-02 | 2008-03-06 | F. Hoffmann-La Roche Ag | 5-substituierte chinazolinonderivate |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| WO2005089804A2 (en) * | 2004-03-16 | 2005-09-29 | Pfizer Limited | Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
| FR2870846B1 (fr) | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| ES2552804T3 (es) | 2005-05-04 | 2015-12-02 | Evotec Ag | Compuestos heterocíclicos condensados, y sus composiciones y usos |
| EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
| CN101641339B (zh) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | 用于预防和治疗心血管疾病的化合物 |
| US20080186971A1 (en) * | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| ES2566387T3 (es) | 2007-04-02 | 2016-04-12 | Evotec Ag | Compuestos heterocíclicos condensados de pirid-2-ilo, y composiciones y usos de los mismos |
| DK2139334T3 (da) | 2007-04-17 | 2013-09-23 | Evotec Ag | Kondenserede heterocykliske 2-cyanophenylforbindelser og sammensætninger og anvendelser deraf |
| US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US8859538B2 (en) * | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| BRPI0812504B8 (pt) | 2007-06-21 | 2021-05-25 | Cara Therapeutics Inc | composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero |
| WO2009011904A1 (en) * | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| CN101417999A (zh) * | 2007-10-25 | 2009-04-29 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
| EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND ITS USE |
| EP3085699B1 (en) | 2008-07-31 | 2022-03-02 | Firmenich Incorporated | Processes for making sweet taste enhancers |
| AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
| MX374414B (es) | 2009-04-22 | 2025-03-06 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| EP2467382B1 (en) * | 2009-08-17 | 2014-06-25 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine pde10 inhibitors |
| EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6551936B2 (ja) | 2012-08-06 | 2019-07-31 | セノミックス インコーポレイテッドＳｅｎｏｍｙｘ， Ｉｎｃ． | 甘味香味修飾因子 |
| JP6307087B2 (ja) * | 2012-10-15 | 2018-04-04 | レスバーロジックス コーポレイション | ベンズアミド化合物の合成に有用な化合物 |
| JO3155B1 (ar) | 2013-02-19 | 2017-09-20 | Senomyx Inc | معدِّل نكهة حلوة |
| JP6464171B2 (ja) | 2013-12-20 | 2019-02-06 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 縮合イミダゾリル誘導体、それらの調製および薬剤としての使用 |
| LT3149002T (lt) * | 2014-05-28 | 2018-07-10 | F. Hoffmann-La Roche Ag | 5-oksa-2-azabiciklo[2.2.2]oktan-4-ilo ir 5-oksa-2-azabiciklo[2.2.1]heptan-4-ilo dariniai kaip taar1 moduliatoriai |
| CN107530356A (zh) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| CN105153048B (zh) * | 2015-07-31 | 2017-10-24 | 苏州大学 | 一种2,4‑喹唑啉二酮类化合物的制备方法 |
| CN105237455A (zh) * | 2015-10-14 | 2016-01-13 | 湖南华腾制药有限公司 | 一种3-取代氮杂环丁烷的制备方法 |
| ES2883285T3 (es) | 2015-12-17 | 2021-12-07 | Merck Patent Gmbh | Antagonistas de tlr7/8 y sus usos |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| RU2758686C2 (ru) * | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| MX2021001193A (es) | 2018-08-07 | 2021-04-28 | Firmenich Incorporated | 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4085213A (en) * | 1976-01-28 | 1978-04-18 | Pfizer Inc. | Tetrazolo[A]quinazol-5-ones antiallergy and antiulcer agents |
| NZ325248A (en) * | 1995-12-23 | 1999-09-29 | Pfizer Res & Dev | Quinoline and quinazoline compounds useful in therapy |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| KR100554813B1 (ko) * | 2001-01-02 | 2006-02-22 | 에프. 호프만-라 로슈 아게 | 알파 1에이/비 아드레날린성 수용체 길항제로서의퀴나졸론 유도체 |
-
2002
- 2002-03-14 GB GBGB0206033.3A patent/GB0206033D0/en not_active Ceased
-
2003
- 2003-03-05 WO PCT/IB2003/000998 patent/WO2003076427A1/en not_active Ceased
- 2003-03-05 MX MXPA04008939A patent/MXPA04008939A/es unknown
- 2003-03-05 AT AT03743965T patent/ATE339414T1/de not_active IP Right Cessation
- 2003-03-05 ES ES03743965T patent/ES2271618T3/es not_active Expired - Lifetime
- 2003-03-05 EP EP03743965A patent/EP1483257B1/en not_active Expired - Lifetime
- 2003-03-05 BR BR0308407-8A patent/BR0308407A/pt not_active IP Right Cessation
- 2003-03-05 AU AU2003209594A patent/AU2003209594A1/en not_active Abandoned
- 2003-03-05 DE DE60308332T patent/DE60308332T2/de not_active Expired - Fee Related
- 2003-03-05 JP JP2003574644A patent/JP2005532275A/ja not_active Withdrawn
- 2003-03-05 CA CA002479016A patent/CA2479016A1/en not_active Abandoned
- 2003-03-11 PE PE2003000247A patent/PE20040265A1/es not_active Application Discontinuation
- 2003-03-11 UY UY27711A patent/UY27711A1/es not_active Application Discontinuation
- 2003-03-12 AR ARP030100858A patent/AR038949A1/es unknown
- 2003-03-12 US US10/387,106 patent/US6936619B2/en not_active Expired - Fee Related
- 2003-03-13 TW TW092105474A patent/TW200305420A/zh unknown
- 2003-03-13 HN HN2003000100A patent/HN2003000100A/es unknown
- 2003-03-14 PA PA20038569501A patent/PA8569501A1/es unknown
- 2003-03-14 GT GT200300059A patent/GT200300059A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0308407A (pt) | 2005-01-11 |
| HN2003000100A (es) | 2003-12-15 |
| DE60308332T2 (de) | 2007-01-11 |
| GB0206033D0 (en) | 2002-04-24 |
| TW200305420A (en) | 2003-11-01 |
| DE60308332D1 (de) | 2006-10-26 |
| WO2003076427A8 (en) | 2004-10-07 |
| PA8569501A1 (es) | 2003-12-10 |
| EP1483257B1 (en) | 2006-09-13 |
| US6936619B2 (en) | 2005-08-30 |
| UY27711A1 (es) | 2003-10-31 |
| US20040029859A1 (en) | 2004-02-12 |
| JP2005532275A (ja) | 2005-10-27 |
| ATE339414T1 (de) | 2006-10-15 |
| MXPA04008939A (es) | 2004-11-26 |
| AU2003209594A1 (en) | 2003-09-22 |
| GT200300059A (es) | 2003-10-15 |
| PE20040265A1 (es) | 2004-05-01 |
| EP1483257A1 (en) | 2004-12-08 |
| ES2271618T3 (es) | 2007-04-16 |
| CA2479016A1 (en) | 2003-09-18 |
| WO2003076427A1 (en) | 2003-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038949A1 (es) | Compuestos de quinazolina utiles en terapia, procedimiento de preparacion y compuesto util en su preparacion | |
| ES2092316T3 (es) | Agentes antianginosos de purinona. | |
| PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
| PE20010736A1 (es) | PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| PE20010635A1 (es) | Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| PE20030129A1 (es) | Imidazotriazinas | |
| PE20010737A1 (es) | PIRAZOLO [4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| PE20071100A1 (es) | Derivados de azepinoindol como agentes farmaceuticos | |
| PE20060459A1 (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA | |
| ES2100572T3 (es) | Esteres de carbonato de la rapamicina como agentes inmunosupresores. | |
| PE68699A1 (es) | Pirazolopirimidonas para disfuncion sexual | |
| CO6210776A2 (es) | Diaminopirimidinas como fungicidas | |
| PE20010637A1 (es) | Derivados del acido aminodicarboxilico como estimulantes de la guanilato ciclasa | |
| DE59308619D1 (de) | Germicide wirkstoffkombinationen | |
| AR054078A1 (es) | Procedimiento para la preparacion de dihidropteridinonas | |
| PE20030808A1 (es) | Derivados triciclicos heterociclicos como antagonistas receptores de trombina | |
| RU2008112290A (ru) | Производные пиридазинона, используемые для лечения боли | |
| AR247886A1 (es) | Procedimiento para la preparacion de un compuesto biciclico heterociclico y una sal farmaceuticamente aceptable del mismo | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20001114A1 (es) | PIRAZOLOPIRIMIDINONAS INHIBIDORAS DE GMPc PDE5 PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL | |
| MA30756B1 (fr) | Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1 | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| CO4650040A1 (es) | Antagonistas oxadiazol y tiadiazol del receptor muscarinico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |